GPR65 and neoplasm: As our tumour-antigen killing system showed a GPR65 antagonist-driven increased T cell cytotoxicity, we assessed any correlation with T cell functional phenotypes by assessing TCR-driven T cell activation markers, proliferation and intracellular IFN-γ production.